Skip to main content
Adlon's ADHD candidate approved by FDA

Adlon Therapeutics' Adhansia XR, or methylphenidate HCl extended release, has been approved by the FDA as a treatment for patients age 6 and older with attention-deficit/hyperactivity disorder. The decision was backed by data from four studies, in which patients who were treated with Adhansia XR significantly improved versus placebo use.

Full Story: